At Axion BioSystems, our goal is to help you non-invasively evaluate your cells. Whether tracking the growth and death of cancer cells or monitoring the intricate, electrically-active behavior of excitable cells (e.g. neurons and cardiomyocytes), our innovative and award-winning products are designed to help you investigate the function of your cells in an easy-to-use, in vitro assay.
Axion initially launched the first commercial multi-well MEA system, the Maestro™, an easy-to-use, non-invasive instrument that measures functional electrical signals from brain and heart cells. We’ve since continued to expand on the promise of this label free, electrode-based technology. Recently, we introduced the Maestro Z, providing functional measures of cell growth, with specific applications in immuno-oncology and immuno-therapies. Axion has a steady pipeline of innovative, industry-leading products that increase throughput, functionality and information.
Our commitment to your discoveries also includes expert knowledge of the biological applications our technology enables. We are a trusted scientific partner in many research collaborations and hope you’ll reach out to us to discuss how Axion’s Maestro Pro, Maestro Edge, and Maestro Z can advance your journey to learn more about how your cells function.
Tom O’Brien co-founded Axion in 2008 after the sale of Intermagnetics General Corporation (NASDAQ: IMGC) to Philips Medical Systems. At Intermagnetics, he held the role of Executive Vice President, Corporate Development and President, Invivo Medical Devices. Prior to that, he has held various senior executive positions in both public and private companies, in the U.S. and abroad. In 2019, he engineered the spin-out of BioCircuit Technologies, an early stage company developing devices that monitor and control peripheral nerves. Tom holds a Bachelor’s Degree in Industrial Engineering from Georgia Tech and an MBA from the University of Chicago.
Jim Ross was previously a product development engineer for Advanced Micro Devices and the co-founder of Nanogrip Technologies, maker of micro-scale devices used to manipulate MEMs components. He has over a decade of experience in MEMS fabrication, analog circuit design, and neural interfacing technology. During his tenure at the Microelectronics Research Center and the Laboratory for Neuroengineering, he was instrumental in producing over a dozen critically enabling technologies for the manipulation and sensing of neural tissue (many of which are patent pending). Jim received a Bachelor of Science degree in Electrical Engineering from Louisiana State University and a Doctorate in Biomedical Engineering from Georgia Tech.
Glenn Epstein, Chairman
Glenn Epstein was most recently Chairman and CEO of Intermagnetics General Corporation (NASDAQ: IMGC). He began his career as an engineer at General Electric before moving to the U.K. to take on progressive management roles with Oxford Instruments plc. Glenn joined Intermagnetics in 1997 as President and COO, took over as CEO in 1999 and was elected Chairman in 2002. He led the company through multiple years of high growth until negotiating the sale of Intermagnetics to Royal Philips for $1.3 billion. Currently, Glenn serves on the boards of Fuel Cell Energy (NASDAQ:FCEL) and X-Ray Optical Systems. He received a BS in Mechanical Engineering from the University of Vermont.
Michelle Jarrard, Board Member
Michelle Jarrard is the Managing Director for the GRA Venture Fund, LLC, a private investment fund providing early-stage capital to Georgia based technology companies. She oversees the Fund’s investment decisions and performance. Prior to joining the Fund, Michelle was a Senior Partner at McKinsey & Company. She served as the firm’s Global Chief HR and Talent Officer. She is currently on the Board of Trustees for Children’s Healthcare of Atlanta and a Trustee of the Georgia Tech Foundation. Michelle earned her MBA from Harvard Business School and a Bachelor’s Degree in Industrial Engineering from Georgia Institute of Technology, with highest honors.
Jay Teich, Board Member
Jay Teich, founder and CEO of Seahorse Bioscience, led the development and commercialization of instruments that enable scientists to study metabolism in living cells. In collaboration with top academic and industry leaders, Seahorse added a new dimension to the study of cellular function while creating a robust new market. In 2015, Agilent Technologies acquired Seahorse for $243MM. Prior to Seahorse, Jay led a management buyout of Inframetrics Corp, technology leaders in thermal imaging cameras. Following a period of rapid growth, Jay merged the company with FLIR Corporation to form the world’s largest thermal imaging company now over $1 billion in sales. Jay is an Electrical Engineering graduate of Lehigh University.
Jim Filippini | Vice President, Global Sales
David Stahl | Director, Software Development
Rob Grier | Director, Operations
Amanda Preyer, PhD | Director,Hardware
Andy Heckerling | Director, Advanced Development
Daniel Millard, PhD | Applications Director
Mike Clements, PhD | Vice President, Marketing
Robert Selby | Accounting Manager
Andrew Willsie | MEMS Manager
Dan Amend | Regional Sales Director, NA East
Jayne Ingram | Regional Sales Director, Europe
James Guo | Regional Sales Director, APAC
Launch your career in one of the fastest growing and emerging life science fields.